Your browser doesn't support javascript.
loading
Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis.
Si, Lulu; Jin, Yunyan; Zhao, Dongni; Yu, Lixia; Cao, Huankun.
  • Si L; Lulu Si, Department of Rheumatology and Immunology, Yiwu Central Hospital, 519 Nanmen Street, Yiwu, Zhejiang Province 322000, P.R. China.
  • Jin Y; Yunyan Jin, Department of Rheumatology and Immunology, Yiwu Central Hospital, 519 Nanmen Street, Yiwu, Zhejiang Province 322000, P.R. China.
  • Zhao D; Dongni Zhao, Department of Rheumatology and Immunology, Yiwu Central Hospital, 519 Nanmen Street, Yiwu, Zhejiang Province 322000, P.R. China.
  • Yu L; Lixia Yu, Department of Rheumatology and Immunology, Yiwu Central Hospital, 519 Nanmen Street, Yiwu, Zhejiang Province 322000, P.R. China.
  • Cao H; Huankun Cao, Department of Ultrasound, Yiwu Central Hospital, Yiwu, Zhejiang Province 322000, P.R. China.
Pak J Med Sci ; 38(4Part-II): 976-980, 2022.
Article en En | MEDLINE | ID: mdl-35634625
ABSTRACT

Objectives:

To explore the effect of glucocorticoids combined with disease modifying anti-rheumatic drugs in the treatment of symptoms in patients with rheumatoid arthritis.

Methods:

Medical records of patients with rheumatoid arthritis treated in the Rheumatology and Immunology Department of Yiwu Central Hospital from March 2020 to March 2021 were selected. A total of 38 patients were treated with disease modifying anti-rheumatic drugs Group-I and 44 patients were treated with disease modifying anti-rheumatic drugs and glucocorticoids Group-II. The symptom improvement of the two groups were compared and analyzed Serological indexes and adverse reactions.

Results:

Swollen joint counts (SJC), tender joint counts (TJC), rheumatoid arthritis disease activity evaluation form (DAS28) score, erythrocyte sedimentation rate, levels of ESR, C-reaction protein (CRP) and rheumatoid factor (RF) of Group-II patients were lower than those in Group-I (P<0.05). The adverse reaction rate in Group-II patients was 12.20%, which was similar to that of Group-I patients. There was no significant difference in 9.76% of the patients (P>0.05).

Conclusion:

The combination of glucocorticoids and disease modifying anti-rheumatic drugs in the treatment of patients with rheumatoid arthritis is safe can further improve their symptoms and serological indexes, and will not lead to increased adverse reactions.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Año: 2022 Tipo del documento: Article